Cargando…

Psoriasis drug development and GWAS interpretation through in silico analysis of transcription factor binding sites

BACKGROUND: Psoriasis is a cytokine-mediated skin disease that can be treated effectively with immunosuppressive biologic agents. These medications, however, are not equally effective in all patients and are poorly suited for treating mild psoriasis. To develop more targeted therapies, interfering w...

Descripción completa

Detalles Bibliográficos
Autores principales: Swindell, William R, Sarkar, Mrinal K, Stuart, Philip E, Voorhees, John J, Elder, James T, Johnston, Andrew, Gudjonsson, Johann E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392043/
https://www.ncbi.nlm.nih.gov/pubmed/25883770
http://dx.doi.org/10.1186/s40169-015-0054-5
_version_ 1782365914969145344
author Swindell, William R
Sarkar, Mrinal K
Stuart, Philip E
Voorhees, John J
Elder, James T
Johnston, Andrew
Gudjonsson, Johann E
author_facet Swindell, William R
Sarkar, Mrinal K
Stuart, Philip E
Voorhees, John J
Elder, James T
Johnston, Andrew
Gudjonsson, Johann E
author_sort Swindell, William R
collection PubMed
description BACKGROUND: Psoriasis is a cytokine-mediated skin disease that can be treated effectively with immunosuppressive biologic agents. These medications, however, are not equally effective in all patients and are poorly suited for treating mild psoriasis. To develop more targeted therapies, interfering with transcription factor (TF) activity is a promising strategy. METHODS: Meta-analysis was used to identify differentially expressed genes (DEGs) in the lesional skin from psoriasis patients (n = 237). We compiled a dictionary of 2935 binding sites representing empirically-determined binding affinities of TFs and unconventional DNA-binding proteins (uDBPs). This dictionary was screened to identify “psoriasis response elements” (PREs) overrepresented in sequences upstream of psoriasis DEGs. RESULTS: PREs are recognized by IRF1, ISGF3, NF-kappaB and multiple TFs with helix-turn-helix (homeo) or other all-alpha-helical (high-mobility group) DNA-binding domains. We identified a limited set of DEGs that encode proteins interacting with PRE motifs, including TFs (GATA3, EHF, FOXM1, SOX5) and uDBPs (AVEN, RBM8A, GPAM, WISP2). PREs were prominent within enhancer regions near cytokine-encoding DEGs (IL17A, IL19 and IL1B), suggesting that PREs might be incorporated into complex decoy oligonucleotides (cdODNs). To illustrate this idea, we designed a cdODN to concomitantly target psoriasis-activated TFs (i.e., FOXM1, ISGF3, IRF1 and NF-kappaB). Finally, we screened psoriasis-associated SNPs to identify risk alleles that disrupt or engender PRE motifs. This identified possible sites of allele-specific TF/uDBP binding and showed that PREs are disproportionately disrupted by psoriasis risk alleles. CONCLUSIONS: We identified new TF/uDBP candidates and developed an approach that (i) connects transcriptome informatics to cdODN drug development and (ii) enhances our ability to interpret GWAS findings. Disruption of PRE motifs by psoriasis risk alleles may contribute to disease susceptibility. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40169-015-0054-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4392043
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-43920432015-04-16 Psoriasis drug development and GWAS interpretation through in silico analysis of transcription factor binding sites Swindell, William R Sarkar, Mrinal K Stuart, Philip E Voorhees, John J Elder, James T Johnston, Andrew Gudjonsson, Johann E Clin Transl Med Research BACKGROUND: Psoriasis is a cytokine-mediated skin disease that can be treated effectively with immunosuppressive biologic agents. These medications, however, are not equally effective in all patients and are poorly suited for treating mild psoriasis. To develop more targeted therapies, interfering with transcription factor (TF) activity is a promising strategy. METHODS: Meta-analysis was used to identify differentially expressed genes (DEGs) in the lesional skin from psoriasis patients (n = 237). We compiled a dictionary of 2935 binding sites representing empirically-determined binding affinities of TFs and unconventional DNA-binding proteins (uDBPs). This dictionary was screened to identify “psoriasis response elements” (PREs) overrepresented in sequences upstream of psoriasis DEGs. RESULTS: PREs are recognized by IRF1, ISGF3, NF-kappaB and multiple TFs with helix-turn-helix (homeo) or other all-alpha-helical (high-mobility group) DNA-binding domains. We identified a limited set of DEGs that encode proteins interacting with PRE motifs, including TFs (GATA3, EHF, FOXM1, SOX5) and uDBPs (AVEN, RBM8A, GPAM, WISP2). PREs were prominent within enhancer regions near cytokine-encoding DEGs (IL17A, IL19 and IL1B), suggesting that PREs might be incorporated into complex decoy oligonucleotides (cdODNs). To illustrate this idea, we designed a cdODN to concomitantly target psoriasis-activated TFs (i.e., FOXM1, ISGF3, IRF1 and NF-kappaB). Finally, we screened psoriasis-associated SNPs to identify risk alleles that disrupt or engender PRE motifs. This identified possible sites of allele-specific TF/uDBP binding and showed that PREs are disproportionately disrupted by psoriasis risk alleles. CONCLUSIONS: We identified new TF/uDBP candidates and developed an approach that (i) connects transcriptome informatics to cdODN drug development and (ii) enhances our ability to interpret GWAS findings. Disruption of PRE motifs by psoriasis risk alleles may contribute to disease susceptibility. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40169-015-0054-5) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2015-03-19 /pmc/articles/PMC4392043/ /pubmed/25883770 http://dx.doi.org/10.1186/s40169-015-0054-5 Text en © Swindell et al.; licensee Springer. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
spellingShingle Research
Swindell, William R
Sarkar, Mrinal K
Stuart, Philip E
Voorhees, John J
Elder, James T
Johnston, Andrew
Gudjonsson, Johann E
Psoriasis drug development and GWAS interpretation through in silico analysis of transcription factor binding sites
title Psoriasis drug development and GWAS interpretation through in silico analysis of transcription factor binding sites
title_full Psoriasis drug development and GWAS interpretation through in silico analysis of transcription factor binding sites
title_fullStr Psoriasis drug development and GWAS interpretation through in silico analysis of transcription factor binding sites
title_full_unstemmed Psoriasis drug development and GWAS interpretation through in silico analysis of transcription factor binding sites
title_short Psoriasis drug development and GWAS interpretation through in silico analysis of transcription factor binding sites
title_sort psoriasis drug development and gwas interpretation through in silico analysis of transcription factor binding sites
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392043/
https://www.ncbi.nlm.nih.gov/pubmed/25883770
http://dx.doi.org/10.1186/s40169-015-0054-5
work_keys_str_mv AT swindellwilliamr psoriasisdrugdevelopmentandgwasinterpretationthroughinsilicoanalysisoftranscriptionfactorbindingsites
AT sarkarmrinalk psoriasisdrugdevelopmentandgwasinterpretationthroughinsilicoanalysisoftranscriptionfactorbindingsites
AT stuartphilipe psoriasisdrugdevelopmentandgwasinterpretationthroughinsilicoanalysisoftranscriptionfactorbindingsites
AT voorheesjohnj psoriasisdrugdevelopmentandgwasinterpretationthroughinsilicoanalysisoftranscriptionfactorbindingsites
AT elderjamest psoriasisdrugdevelopmentandgwasinterpretationthroughinsilicoanalysisoftranscriptionfactorbindingsites
AT johnstonandrew psoriasisdrugdevelopmentandgwasinterpretationthroughinsilicoanalysisoftranscriptionfactorbindingsites
AT gudjonssonjohanne psoriasisdrugdevelopmentandgwasinterpretationthroughinsilicoanalysisoftranscriptionfactorbindingsites